TSHA Taysha Gene Therapies, Inc. - Common Stock
NASDAQ · Biotechnology · View on SEC EDGAR ↗ close Oct 2, 2026 10-K/10-Q Aug 11, 2026
$4.63
· of 52w range
· above low
· to high
$3.6952w low
$7.3052w high
Market Cap (MRQ)
$1.51B
P/E (TTM)
-11.0
EPS (TTM)
$-0.42
Revenue (TTM)
$5M
your badges
52W Range
$4–$7
Analyst Rating
BUY
Price Target
$13
P/E
-11.0
ROE
-47.1%
Net Profit Margin
-2728.0%
Your badge strip is empty — pin a metric anywhere on this page.
TSHA Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
Price
$4.63
Market Cap (MRQ)
$1.51B
P/E (TTM)
-11.0
EPS (TTM)
$-0.42
Revenue (TTM)
$5M
ROE (TTM)
-47.1%
Debt/Equity (MRQ)
0.1
52W Range
$4–$7
TSHA Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
range
bars
Bar granularity adapts to the selected period — hover the chart to see open/high/low/close for a bar.
10-Year Performance Revenue, net income, margins and EPS trends
Revenue$10M2022-12-31 → 2025-12-31
EPS$-0.342021-12-31 → 2025-12-31
Free Cash Flow$-94M2020-12-31 → 2025-12-31
Net margin-2728.0%2023-12-31 → 2025-12-31
Valuation & Ratios
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
| Metric | 5Y trend | TSHA | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| P/E (TTM) | -11.05Y avg ≈-5.2 | ≈-5.2 | · | · | |
| P/S (TTM) | 274.65Y avg ≈74.8 | ≈74.8 | 37.8 | Overvalued | |
| P/B (MRQ) | 3.95Y avg ≈5.1 | ≈5.1 | 3.3 | Overvalued | |
| EV / EBITDA | -9.65Y avg ≈-4.9 | ≈-4.9 | · | · | |
| Price / FCF (TTM) | -11.45Y avg ≈-7.2 | ≈-7.2 | · | · | |
| Price / Cash Flow (TTM) | -11.45Y avg ≈-7.4 | ≈-7.4 | · | · | |
| EV / Revenue | 108.55Y avg ≈59.6 | ≈59.6 | · | · | |
| EV / FCF | -11.35Y avg ≈-5.6 | ≈-5.6 | · | · | |
| Price / Tangible Book | 5.45Y avg ≈34.2 | ≈34.2 | · | · |
Peer median is calculated on a standardized basis per metric and may not always match the TTM/MRQ basis shown for this stock.
Profitability Gross, operating and net margins; ROE, ROA, ROIC
| Metric | 5Y trend | TSHA | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Operating Margin (TTM) | -2792.3%5Y avg ≈-899.0% | ≈-899.0% | -890.5% | Weak | |
| EBITDA Margin | -1130.7%5Y avg ≈-899.0% | ≈-899.0% | -890.5% | Weak | |
| Net Profit Margin (TTM) | -2728.0%5Y avg ≈-969.7% | ≈-969.7% | -874.4% | Weak | |
| ROA (TTM) | -37.2%5Y avg ≈-61.3% | ≈-61.3% | -41.9% | In line | |
| ROE (TTM) | -47.1%5Y avg ≈-291.9% | ≈-291.9% | -55.3% | Top tier |
Financial Health Debt, liquidity, solvency — balance sheet strength
| Metric | 5Y trend | TSHA | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Debt / Equity (MRQ) | 0.15Y avg ≈0.4 | ≈0.4 | 0.1 | In line | |
| Current Ratio (MRQ) | 17.85Y avg ≈6.2 | ≈6.2 | 6.5 | Strong liquidity | |
| Quick Ratio | 12.05Y avg ≈6.0 | ≈6.0 | 5.5 | Strong liquidity | |
| Long-Term Debt / Equity (MRQ) | 0.15Y avg ≈0.4 | ≈0.4 | · | · |
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
| Metric | 5Y trend | TSHA | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Revenue YoY | 17.3%5Y avg ≈162.9% | ≈162.9% | · | · | |
| Revenue CAGR 3Y | 57.5% | · | · | · |
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
| Metric | 5Y trend | TSHA | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Asset Turnover | 0.05Y avg ≈0.1 | ≈0.1 | 0.1 | Weak | |
| Revenue / Employee | ≈$98.7K | · | · | · |
value · ≈ 5Y avg · industry median · verdict relative to median
Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date
Avg Surprise
0.53%
Next Report
Nov 02, 2026
| Period | Report | EPS Actual | EPS Est | Surprise |
|---|---|---|---|---|
| June 30, 2026 | Aug 17, 2026 | $-0.14 | $-0.12 | -17.7% |
| March 31, 2026 | May 20, 2026 | $-0.12 | $-0.10 | -20.5% |
| Dec. 31, 2025 | $-0.08 | $-0.10 | 18.5% | |
| Sept. 30, 2025 | $-0.09 | $-0.09 | 0.00% | |
| June 30, 2025 | $-0.09 | $-0.08 | -9.1% | |
| March 31, 2025 | $-0.08 | $-0.09 | 15.3% | |
| Dec. 31, 2024 | $-0.07 | $-0.08 | 17.4% |
Full Fundamentals All metrics by year — income statement, balance sheet, cash flow
Income Statement
| Metric | Trend | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | $10M | $8M | $15M | $3M | |
| R&D Expense | $86M | $66M | $57M | $91M | |
| SG&A Expense | $34M | $29M | $30M | $37M | |
| Operating Expenses | $120M | $100M | $88M | $165M | |
| Operating Income | $-110M | $-91M | $-72M | $-162M | |
| Interest Expense | · | · | $5M | $4M | |
| Interest Income | $9M | $7M | $4M | · | |
| Other Non-op | $-291.0K | $-110.0K | $-47.0K | $-18.0K | |
| Income Tax | $0 | $0 | $0 | $0 | |
| Net Income | $-109M | $-89M | $-112M | $-166M | |
| EPS (Basic) | $-0.34 | $-0.36 | $-0.96 | $-3.78 | |
| EPS (Diluted) | $-0.34 | $-0.36 | $-0.96 | $-3.78 | |
| Shares (Basic) | 319,711,972 | 250,134,421 | 116,121,482 | 43,952,015 | |
| Shares (Diluted) | 319,711,972 | 250,134,421 | 116,121,482 | 43,952,015 | |
| EBITDA | $-110M | $-91M | $-72M | · |
Balance Sheet
| Metric | Trend | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Cash & Equivalents | $320M | $139M | $144M | $88M | |
| Prepaid Expense | $4M | $3M | $3M | $9M | |
| Other Current Assets | $802.0K | $308.0K | $292.0K | $466.0K | |
| Current Assets | $325M | $142M | $150M | $96M | |
| PP&E (Net) | $7M | $7M | $11M | $15M | |
| PP&E (Gross) | $11M | $11M | $14M | $17M | |
| Accum. Depreciation | $5M | $4M | $3M | $2M | |
| Other Non-current Assets | $183.0K | $217.0K | $304.0K | $1M | |
| Total Assets | $343M | $160M | $173M | $126M | |
| Accounts Payable | $6M | $4M | $6M | $11M | |
| Current Liabilities | $27M | $26M | $37M | $63M | |
| Capital Leases | $18M | $17M | $19M | $20M | |
| Other Non-current Liabilities | $2M | $1M | $2M | $4M | |
| Total Liabilities | $96M | $89M | $98M | $125M | |
| Long-term Debt | · | · | · | $38M | |
| Total Debt | $50M | $44M | $41M | · | |
| Common Stock | $3.0K | $2.0K | $2.0K | $1.0K | |
| Paid-in Capital | $958M | $678M | $588M | $402M | |
| Retained Earnings | $-711M | $-602M | $-513M | $-401M | |
| AOCI | $-192.0K | $-4M | · | · | |
| Stockholders' Equity | $247M | $72M | $75M | $949.0K | |
| Liabilities + Equity | $343M | $160M | $173M | $126M | |
| Shares Outstanding | 285,051,648 | 204,943,306 | 186,960,193 | 63,207,507 |
Cash Flow
| Metric | Trend | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Stock-based Comp | $13M | $13M | $8M | $18M | |
| Operating Cash Flow | $-93M | $-81M | $-73M | $-88M | |
| CapEx | $738.0K | $374.0K | $4M | $21M | |
| Investing Cash Flow | $-604.0K | $-363.0K | $-7M | $-25M | |
| Stock Issued | · | · | $500.0K | · | |
| Financing Cash Flow | $275M | $77M | $136M | $52M | |
| Net Change in Cash | $181M | $-5M | $56M | $-61M | |
| Free Cash Flow | $-94M | $-82M | $-77M | · |
Profitability
| Metric | Trend | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Operating Margin | -1130.7% | -1097.5% | -468.8% | · | |
| Net Margin | -1115.3% | -1071.6% | -722.1% | · | |
| EBITDA Margin | -1130.7% | -1097.5% | -468.8% | · | |
| ROA | -43.3% | -53.6% | -74.6% | · | |
| ROE | -44.0% | -111.4% | -864.1% | · |
Liquidity & Solvency
| Metric | Trend | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Current Ratio | 12.2 | 5.4 | 4.1 | · | |
| Quick Ratio | 12.0 | 5.3 | 3.9 | · | |
| Debt / Equity | 0.2 | 0.6 | 0.5 | · | |
| LT Debt / Equity | 0.2 | 0.6 | 0.5 | · | |
| Interest Coverage | · | · | -14.5 | · |
Efficiency
| Metric | Trend | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.1 | 0.1 | · |
Per Share
| Metric | Trend | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Book Value / Share | $0.87 | $0.35 | $0.40 | · | |
| Revenue / Share | $0.03 | $0.03 | $0.13 | · | |
| Cash Flow / Share | $-0.29 | $-0.32 | $-0.63 | · | |
| Cash / Share | $1.12 | $0.68 | $0.77 | · | |
| EPS (TTM) | $-0.34 | $-0.36 | $-0.96 | $-3.78 |
Growth Rates
| Metric | Trend | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue YoY | 17.3% | -46.1% | 517.6% | · | |
| Revenue CAGR 3Y | 57.5% | · | · | · |
Valuation (TTM)
| Metric | Trend | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue TTM | $10M | $8M | $15M | $3M | |
| Net Income TTM | $-109M | $-89M | $-112M | $-166M | |
| Market Cap | $1.57B | $355M | $331M | · | |
| Enterprise Value | $1.30B | $259M | $227M | · | |
| P/E | -16.2 | -4.8 | -1.8 | -0.6 | |
| P/S | 160.4 | 42.5 | 21.4 | · | |
| P/B | 6.3 | 5.0 | 4.4 | · | |
| P / Tangible Book | 6.3 | 5.0 | 4.4 | 150.5 | |
| P / Cash Flow | -16.8 | -4.4 | -4.5 | · | |
| P / FCF | -16.7 | -4.3 | -4.3 | · | |
| EV / EBITDA | -11.7 | -2.8 | -3.1 | · | |
| EV / FCF | -13.8 | -3.2 | -3.0 | · | |
| EV / Revenue | 132.8 | 31.1 | 14.7 | · | |
| Earnings Yield | -6.2% | -20.8% | -54.2% | -167.3% |
Income Statement
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $5M | $0 | $2M | $2M | $2M | $2M | $1M | $3M | $4M | $5M | $2M | $5M | |
| R&D Expense | $39M | $34M | $25M | $26M | $20M | $16M | $15M | $15M | $15M | $21M | $13M | $12M | $20M | $13M | |
| SG&A Expense | $12M | $10M | $9M | $8M | $9M | $8M | $7M | $8M | $7M | $7M | $7M | $9M | $6M | $9M | |
| Operating Expenses | $47M | $43M | $34M | $34M | $29M | $24M | $22M | $28M | $22M | $28M | $20M | $21M | $26M | $21M | |
| Operating Income | $-47M | $-43M | $-28M | $-34M | $-27M | $-21M | $-20M | $-26M | $-21M | $-24M | $-16M | $-16M | $-23M | $-17M | |
| Interest Expense | · | · | · | · | · | · | · | · | $27.0K | $29.0K | · | $1M | $1M | $1M | |
| Interest Income | $2M | $3M | $3M | $3M | $2M | $1M | $2M | $2M | $1M | $2M | $2M | $1M | · | · | |
| Other Non-op | $-88.0K | $-31.0K | $-30.0K | $-37.0K | $-237.0K | $13.0K | $-66.0K | $-81.0K | $42.0K | $-5.0K | $-23.0K | $-19.0K | $3.0K | $-8.0K | |
| Income Tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | · | $0 | $0 | $0 | |
| Net Income | $-47M | $-42M | $-28M | $-33M | $-27M | $-22M | $-19M | $-26M | $-21M | $-24M | $48M | $-117M | $-25M | $-18M | |
| EPS (Basic) | $-0.13 | $-0.12 | $-0.08 | $-0.09 | $-0.09 | $-0.08 | $-0.07 | $-0.10 | $-0.09 | $-0.10 | $0.63 | $-0.93 | $-0.38 | $-0.28 | |
| EPS (Diluted) | $-0.13 | $-0.12 | $-0.08 | $-0.09 | $-0.09 | $-0.08 | $-0.07 | $-0.10 | $-0.09 | $-0.10 | $0.63 | $-0.93 | $-0.38 | $-0.28 | |
| Shares (Basic) | 369,044,040 | 366,632,827 | · | 353,309,524 | 297,988,978 | 269,306,331 | · | 267,824,045 | 232,821,553 | 231,249,344 | · | 125,700,799 | 64,244,531 | 63,260,905 | |
| Shares (Diluted) | 369,044,040 | 366,632,827 | · | 353,309,524 | 297,988,978 | 269,306,331 | · | 267,824,045 | 232,821,553 | 231,249,344 | · | 125,700,799 | 64,244,531 | 63,260,905 | |
| EBITDA | $-47M | $-43M | · | $-34M | $-27M | $-21M | · | $-26M | $-21M | $-24M | · | $-16M | $-23M | $-17M |
Balance Sheet
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $455M | $277M | $320M | $297M | $313M | $117M | $139M | $158M | $173M | $124M | $144M | $164M | $45M | $63M | |
| Prepaid Expense | $6M | $5M | $4M | $2M | $3M | $4M | $3M | $3M | $3M | $4M | $3M | $6M | $9M | $9M | |
| Other Current Assets | $851.0K | $1M | $802.0K | $456.0K | $657.0K | $536.0K | $308.0K | $465.0K | $206.0K | $149.0K | $292.0K | $404.0K | $510.0K | $532.0K | |
| Current Assets | $461M | $282M | $325M | $300M | $316M | $121M | $142M | $162M | $178M | $131M | $150M | $172M | $54M | $72M | |
| PP&E (Net) | $2M | $6M | $7M | $7M | $7M | $7M | $7M | $8M | $11M | $11M | $11M | $11M | $14M | $15M | |
| PP&E (Gross) | $8M | $11M | $11M | $11M | $11M | $11M | $11M | $12M | $14M | $14M | $14M | $14M | $16M | $17M | |
| Accum. Depreciation | $5M | $5M | $5M | $4M | $4M | $4M | $4M | $4M | $4M | $3M | $3M | $3M | $2M | $2M | |
| Other Non-current Assets | $106.0K | $181.0K | $183.0K | $184.0K | $186.0K | $188.0K | $217.0K | $220.0K | $288.0K | $304.0K | $304.0K | $304.0K | $304.0K | $1M | |
| Total Assets | $470M | $300M | $343M | $317M | $333M | $138M | $160M | $180M | $200M | $153M | $173M | $196M | $82M | $102M | |
| Accounts Payable | $9M | $5M | $6M | $5M | $8M | $4M | $4M | $5M | $9M | $10M | $6M | $8M | $11M | $9M | |
| Current Liabilities | $26M | $20M | $27M | $29M | $25M | $23M | $26M | $29M | $34M | $39M | $37M | $180M | $51M | $54M | |
| Capital Leases | $6M | $18M | $18M | $17M | $17M | $17M | $17M | $18M | $18M | $18M | $19M | $19M | $20M | $20M | |
| Other Non-current Liabilities | $2M | $2M | $2M | $2M | $1M | $1M | $1M | $1M | $1M | $2M | $2M | $4M | $4M | $4M | |
| Total Liabilities | $83M | $88M | $96M | $98M | $85M | $83M | $89M | $91M | $92M | $99M | $98M | $245M | $119M | $117M | |
| Long-term Debt | · | · | · | · | · | · | · | · | · | · | · | · | $38M | $38M | |
| Total Debt | $49M | $49M | · | $51M | $41M | $42M | · | $43M | $38M | $41M | · | $39M | $38M | $38M | |
| Common Stock | $3.0K | $3.0K | $3.0K | $3.0K | $3.0K | $2.0K | $2.0K | $2.0K | $2.0K | $2.0K | $2.0K | $2.0K | $1.0K | $1.0K | |
| Paid-in Capital | $1.19B | $965M | $958M | $904M | $900M | $681M | $678M | $675M | $664M | $591M | $588M | $512M | $407M | $404M | |
| Retained Earnings | $-800M | $-754M | $-711M | $-683M | $-651M | $-624M | $-602M | $-584M | $-558M | $-537M | $-513M | $-561M | $-444M | $-419M | |
| AOCI | $769.0K | $985.0K | $-192.0K | $-1M | $-699.0K | $-2M | $-4M | $-2M | $2M | $-251.0K | · | · | · | · | |
| Stockholders' Equity | $387M | $212M | $247M | $219M | $249M | $55M | $72M | $89M | $109M | $54M | $75M | $-49M | $-37M | $-15M | |
| Liabilities + Equity | $470M | $300M | $343M | $317M | $333M | $138M | $160M | $180M | $200M | $153M | $173M | $196M | $82M | $102M | |
| Shares Outstanding | 325,302,280 | 287,276,885 | 285,051,648 | 273,915,373 | 272,730,060 | 205,054,570 | 204,943,306 | 204,943,306 | 201,381,450 | 187,018,275 | 186,960,193 | 186,960,193 | 64,432,637 | 63,473,349 |
Cash Flow
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $6M | $6M | $4M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $2M | $2M | $2M | $2M | |
| Operating Cash Flow | $-40M | $-41M | $-27M | $-24M | $-20M | $-22M | $-18M | $-22M | $-22M | $-20M | $-16M | $-18M | $-19M | $-20M | |
| CapEx | $-1.0K | $24.0K | $250.0K | $108.0K | $2.0K | $378.0K | $-2.0K | $35.0K | $201.0K | $140.0K | $17.0K | $0 | $-48.0K | $4M | |
| Investing Cash Flow | $1.0K | $-3M | $-247.0K | $-48.0K | $62.0K | $-371.0K | $13.0K | $-35.0K | $-201.0K | $-140.0K | $-10.0K | $-3M | $48.0K | $-4M | |
| Stock Issued | · | · | · | · | · | · | · | · | · | · | $0 | · | · | · | |
| Financing Cash Flow | $217M | $711.0K | $50M | $9M | $216M | $-52.0K | $-357.0K | $7M | $70M | $-22.0K | $-4M | $141M | $377.0K | $-370.0K | |
| Net Change in Cash | $176M | $-43M | $23M | $-15M | $196M | $-22M | $-19M | $-15M | $49M | $-20M | $-20M | $119M | $-18M | $-24M | |
| Free Cash Flow | · | $-41M | · | · | · | · | · | · | · | $-20M | · | · | · | $-24M |
Profitability
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | · | · | · | · | -1347.1% | -930.5% | · | -1448.4% | -1915.4% | -713.3% | · | -342.4% | -976.4% | -351.9% | |
| Net Margin | · | · | · | · | -1353.6% | -935.2% | · | -1427.5% | -1882.0% | -705.4% | · | -2467.1% | -1027.1% | -374.5% | |
| EBITDA Margin | · | · | · | · | -1347.1% | -930.5% | · | -1448.4% | -1915.4% | -713.3% | · | -342.4% | -976.4% | -351.9% | |
| ROA | -11.6% | -19.3% | · | -13.2% | -10.1% | -14.8% | · | -13.6% | -14.8% | -18.9% | · | -76.2% | -22.0% | -13.2% | |
| ROE | -14.7% | -31.8% | · | -21.3% | -15.0% | -39.5% | · | -128.6% | -58.3% | -123.7% | · | 616.4% | 1117.1% | -98.5% |
Liquidity & Solvency
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 17.8 | 14.0 | · | 10.5 | 12.5 | 5.4 | · | 5.5 | 5.2 | 3.4 | · | 1.0 | 1.1 | 1.3 | |
| Quick Ratio | 17.5 | 13.8 | · | 10.4 | 12.3 | 5.2 | · | 5.4 | 5.1 | 3.2 | · | 0.9 | 0.9 | 1.2 | |
| Debt / Equity | 0.1 | 0.2 | · | 0.2 | 0.2 | 0.8 | · | 0.5 | 0.3 | 0.8 | · | -0.8 | -1.0 | -2.6 | |
| LT Debt / Equity | 0.1 | 0.2 | · | 0.2 | 0.2 | 0.8 | · | 0.5 | 0.3 | 0.8 | · | -0.8 | -1.0 | -2.6 | |
| Interest Coverage | · | · | · | · | · | · | · | · | -788.9 | -839.0 | · | -11.0 | -16.2 | -12.1 |
Efficiency
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 |
Per Share
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $1.19 | $0.74 | · | $0.80 | $0.91 | $0.27 | · | $0.43 | $0.54 | $0.29 | · | $-0.26 | $-0.58 | $-0.24 | |
| Revenue / Share | $0.00 | $0.00 | · | $0.00 | $0.01 | $0.01 | · | $0.01 | $0.00 | $0.01 | · | $0.04 | $0.04 | $0.07 | |
| Cash Flow / Share | · | $-0.11 | · | · | · | $-0.08 | · | · | · | $-0.09 | · | · | · | $-0.32 | |
| Cash / Share | $1.40 | $0.96 | · | $1.09 | $1.15 | $0.57 | · | $0.77 | $0.86 | $0.66 | · | $0.88 | $0.70 | $1.00 | |
| EPS (TTM) | $-0.42 | $-0.38 | · | $-0.33 | $-0.34 | $-0.34 | · | $0.34 | $-0.49 | $-0.78 | · | $-2.55 | $-2.27 | $-2.74 |
Valuation (TTM)
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $5M | $7M | · | $6M | $8M | $7M | · | $10M | $13M | $14M | · | · | · | · | |
| Net Income TTM | $-150M | $-130M | · | $-100M | $-93M | $-87M | · | $-23M | $-114M | $-118M | · | $-214M | $-124M | $-133M | |
| Market Cap | $2.22B | $1.28B | · | $896M | $630M | $285M | · | $412M | $451M | $537M | · | $591M | $43M | $51M | |
| Enterprise Value | $1.81B | $1.06B | · | $649M | $358M | $211M | · | $297M | $316M | $453M | · | $465M | $36M | $25M | |
| P/E | -16.2 | -11.8 | · | -9.9 | -6.8 | -4.1 | · | 5.9 | -4.6 | -3.7 | · | -1.2 | -0.3 | -0.3 | |
| P/S | 403.9 | 171.9 | · | 141.9 | 77.8 | 39.5 | · | 41.5 | 35.0 | 37.9 | · | · | · | · | |
| P/B | 5.7 | 6.1 | · | 4.1 | 2.5 | 5.2 | · | 4.6 | 4.1 | 10.0 | · | -12.0 | -1.1 | -3.4 | |
| P / Tangible Book | 5.7 | 6.1 | · | 4.1 | 2.5 | 5.2 | · | 4.6 | 4.1 | 10.0 | · | · | · | · | |
| P / Cash Flow | · | -31.4 | · | · | · | -12.9 | · | · | · | -27.1 | · | · | · | -2.5 | |
| EV / Revenue | 329.8 | 141.4 | · | 102.9 | 44.2 | 29.2 | · | 30.0 | 24.6 | 32.0 | · | · | · | · | |
| Earnings Yield | -6.2% | -8.5% | · | -10.1% | -14.7% | -24.5% | · | 16.9% | -21.9% | -27.2% | · | -80.7% | -343.4% | -343.4% |
Most recent period on the left · null values shown as ·
Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Revenue | $10M | $8M | $15M | $3M | · |
| Operating Margin % | -1130.7% | -1097.5% | -468.8% | · | · |
| Net Income | $-109M | $-89M | $-112M | $-166M | $-175M |
| Diluted EPS | $-0.34 | $-0.36 | $-0.96 | $-3.78 | $-4.64 |
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Debt / Equity | 0.2 | 0.6 | 0.5 | · | 0.4 |
| Current Ratio | 12.2 | 5.4 | 4.1 | · | 3.1 |
| Quick Ratio | 12.0 | 5.3 | 3.9 | · | 2.9 |
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Free Cash Flow | $-94M | $-82M | $-77M | · | $-132M |
Institutional owners (13F) 221 filers · $2.1B total · As of June 30, 2026
Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.
Holders
221
Value held
$2.1B
New positions
40
Exited positions
23
Institutional activity — Q2 2026 vs prior quarter
| New positions | Exited positions | Increased | Decreased | Net shares change |
|---|---|---|---|---|
| 40 (+5 vs prior Q) | 23 (-7 vs prior Q) | 101 (+29 vs prior Q) | 41 (-10 vs prior Q) | +34.4M |
Compared to Q1 2026. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair.
| Institution | Value | Shares | % of tracked 13F | Type |
|---|---|---|---|---|
| Avoro Capital Advisors LLC | $162,683,327 | 23,888,888 | 7.59% | Shares |
| RA CAPITAL MANAGEMENT, L.P. | $160,413,963 | 23,555,648 | 7.48% | Shares |
| GOLDMAN SACHS GROUP INC | $154,676,334 | 22,713,118 | 7.21% | Shares |
| BlackRock, Inc. | $140,912,023 | 20,691,927 | 6.57% | Shares |
| Vestal Point Capital, LP | $132,216,150 | 19,415,000 | 6.17% | Shares |
| MORGAN STANLEY | $112,279,731 | 16,487,479 | 5.24% | Shares |
| RTW INVESTMENTS, LP | $92,345,357 | 13,560,258 | 4.31% | Shares |
| FMR LLC | $90,820,969 | 13,336,413 | 4.24% | Shares |
| VANGUARD CAPITAL MANAGEMENT LLC | $84,979,232 | 12,478,595 | 3.96% | Shares |
| STATE STREET CORP | $77,783,275 | 11,421,920 | 3.63% | Shares |
| VANGUARD GROUP INC | $72,972,929 | 13,267,805 | 3.40% | Shares |
| Siren, L.L.C. | $67,055,203 | 9,846,579 | 3.13% | Shares |
| Octagon Capital Advisors LP | $66,010,992 | 9,693,244 | 3.08% | Shares |
| GEODE CAPITAL MANAGEMENT, LLC | $44,685,322 | 6,560,394 | 2.08% | Shares |
| Polar Capital Holdings Plc | $34,847,676 | 5,117,133 | 1.63% | Shares |
| MPM BIOIMPACT LLC | $30,645,000 | 4,500,000 | 1.43% | Shares |
| D. E. Shaw & Co., Inc. | $29,954,821 | 4,398,652 | 1.40% | Shares |
| BAKER BROS. ADVISORS LP | $27,272,388 | 4,004,756 | 1.27% | Shares |
| WELLINGTON MANAGEMENT GROUP LLP | $27,073,870 | 3,975,605 | 1.26% | Shares |
| HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND | $26,460,262 | 3,885,501 | 1.23% | Shares |
| GordonMD Global Investments LP | $24,501,508 | 723,185 | 1.14% | Shares |
| Casdin Capital, LLC | $22,132,500 | 3,250,000 | 1.03% | Shares |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $21,383,461 | 3,140,009 | 1.00% | Shares |
| ADAR1 Capital Management, LLC | $20,705,573 | 3,040,466 | 0.97% | Shares |
| Pictet Asset Management Holding SA | $18,868,474 | 2,770,701 | 0.88% | Shares |
| Aberdeen Group plc | $15,847,905 | 2,327,152 | 0.74% | Shares |
| FARALLON CAPITAL MANAGEMENT, L.L.C. | $15,322,500 | 2,250,000 | 0.71% | Shares |
| NORGES BANK | $15,210,816 | 2,233,600 | 0.71% | Shares |
| NORTHERN TRUST CORP | $15,160,491 | 2,226,210 | 0.71% | Shares |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $14,986,733 | 2,200,695 | 0.70% | Shares |
| MILLENNIUM MANAGEMENT LLC | $14,483,767 | 2,126,838 | 0.68% | Shares |
| ORBIMED ADVISORS LLC | $13,620,000 | 2,000,000 | 0.64% | Shares |
| RICE HALL JAMES & ASSOCIATES, LLC | $13,567,079 | 1,992,229 | 0.63% | Shares |
| VANGUARD FIDUCIARY TRUST CO | $12,914,988 | 1,896,474 | 0.60% | Shares |
| B Group, Inc. | $12,261,786 | 1,800,556 | 0.57% | Shares |
| TYBOURNE CAPITAL MANAGEMENT (HK) LTD | $12,099,000 | 3,700,000 | 0.56% | Shares |
| Affinity Asset Advisors, LLC | $11,917,500 | 1,750,000 | 0.56% | Shares |
| BARCLAYS PLC | $11,104,787 | 1,630,659 | 0.52% | Shares |
| CITADEL ADVISORS LLC | $10,455,305 | 1,535,287 | 0.49% | Shares |
| HEIGHTS CAPITAL MANAGEMENT, INC | $10,215,000 | 1,500,000 | 0.48% | Shares |
| Seven Fleet Capital Management LP | $9,940,323 | 1,504,400 | 0.46% | Shares |
| Palo Alto Investors LP | $9,475,311 | 1,391,382 | 0.44% | Shares |
| BANK OF AMERICA CORP /DE/ | $9,349,074 | 1,372,845 | 0.44% | Shares |
| Granahan Investment Management, LLC | $8,888,255 | 1,305,177 | 0.41% | Shares |
| Quantum Private Wealth, LLC | $5,529,903 | 812,027 | 0.26% | Shares |
| FIRST TRUST ADVISORS LP | $5,387,860 | 791,169 | 0.25% | Shares |
| JPMORGAN CHASE & CO | $5,157,078 | 766,282 | 0.24% | Shares |
| Sands Capital Alternatives, LLC | $4,936,385 | 724,873 | 0.23% | Shares |
| Bank of New York Mellon Corp | $4,753,180 | 697,971 | 0.22% | Shares |
| BNP PARIBAS FINANCIAL MARKETS | $4,358,638 | 640,035 | 0.20% | Shares |
Activists & 5%+ owners 4 positions
Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.
| Filer | Filed | Stake | Status | Purpose | Filing |
|---|---|---|---|---|---|
| Paul B Manning, The Paul B. Manning Revocable Trust dated May 10, 2000, The PBM 2023 Grantor Retained Annuity Trust, The PBM 2025 Grantor Retained Annuity Trust, BKB Growth Investments, LLC, BKB G2 Investments, LLC | June 3, 2025 | 9.80% | Amendment | · | SEC |
| Paul B. Manning, The Paul B. Manning Revocable Trust dated May 10, 2000, The PBM 2023 Grantor Retained Annuity Trust, BKB Growth Investments, LLC, BKB G2 Investments, LLC ×3 filings | Aug. 21, 2023 | · | Initial filing | · | SEC |
| Astellas Pharma Inc., Astellas US Holding, Inc., Astellas Gene Therapies, Inc. (f/k/a Audentes Therapeutics, Inc.) ×2 filings | Aug. 18, 2023 | · | Initial filing | · | SEC |
| RA Session II, RA Session II, as Trustee of the Session 2020 Annuity Trust I, RA Session II, as Trustee of the Session 2020 Annuity Trust II | Oct. 5, 2020 | · | Initial filing | Passive investment | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Company insiders 11 insiders · 4 officers · 7 directors
| Insider | Role | Last activity | Shares owned | Buys 12m | Sells 12m | Net 12m |
|---|---|---|---|---|---|---|
| Sean P. Nolan | Chief Executive Officer | Jan. 26, 2026 S | 2,908,257 | 0 | 2 | $-840,196 |
| Kamran Alam | CHIEF FINANCIAL OFFICER | Feb. 4, 2026 S | 1,442,131 | 0 | 3 | $-492,523 |
| Sukumar Nagendran | President and Head of R&D | April 10, 2026 M | 1,136,410 | 0 | 6 | $-4,077,375 |
| Suyash Prasad | CMO and Head of R&D | July 6, 2022 S | 530,589 | 0 | 0 | $0 |
| Alison S Long | Director | June 2, 2025 A | 105,843 | 0 | 0 | $0 |
| Laura Sepp-Lorenzino | Director | June 2, 2025 A | 105,843 | 0 | 0 | $0 |
| John A Stalfort III | Director | June 2, 2025 A | 1,155,224 | 0 | 0 | $0 |
| Phillip B. Donenberg | Director | June 2, 2025 A | 219,954 | 0 | 0 | $0 |
| Kathleen Reape | Director | June 22, 2023 A | · | 0 | 0 | $0 |
| Paul B Manning | 10% owner | May 30, 2025 P | 2,841,704 | 0 | 0 | $0 |
| R.A. Session II | 10% owner | July 13, 2023 S | 8,871,747 | 0 | 0 | $0 |
Insiders from SEC Form 3/4/5 filings; net = open-market P/S only
ETF ownership Held by 34 ETFs
Weight reflects direct equity holdings (N-PORT) only; leveraged or derivative-based funds may hold additional swap exposure not shown.
| Fund | Weight | Units | As of | Source |
|---|---|---|---|---|
| IBRN · iShares Trust | 1.29% | 18,665 SH | Sept. 11, 2026 | Daily |
| BBC · ETFis Series Trust I | 0.69% | 54,433 NS | July 31, 2026 | N-PORT |
| FYC · First Trust Exchange-Traded AlphaDE… | 0.34% | 758,584 NS | July 31, 2026 | N-PORT |
| LABU · Direxion Shares ETF Trust | 0.22% | 189,117 NS | July 31, 2026 | N-PORT |
| ESSC · Strategy Shares | 0.15% | 9,374 NS | July 31, 2026 | N-PORT |
| VFMO · VANGUARD WELLINGTON FUND | 0.11% | 332,492 SH | Aug. 19, 2026 | Daily |
| FYX · First Trust Exchange-Traded AlphaDE… | 0.11% | 256,192 NS | July 31, 2026 | N-PORT |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0.10% | 23,041 SH | Oct. 1, 2026 | Daily |
| IBB · iShares Trust | 0.10% | 2,030,172 SH | Sept. 11, 2026 | Daily |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0.10% | 257,044 SH | Aug. 19, 2026 | Daily |
| IWO · iShares Trust | 0.08% | 2,238,896 SH | Sept. 11, 2026 | Daily |
| FAD · First Trust Exchange-Traded AlphaDE… | 0.07% | 68,720 NS | July 31, 2026 | N-PORT |
| PWS · Pacer Funds Trust | 0.06% | 2,584 NS | July 31, 2026 | N-PORT |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0.05% | 1,379,816 SH | Aug. 19, 2026 | Daily |
| RSSL · Global X Funds | 0.05% | 114,788 NS | July 31, 2026 | N-PORT |
| IWM · iShares Trust | 0.04% | 6,131,004 SH | Sept. 11, 2026 | Daily |
| ISCG · iShares Trust | 0.04% | 66,643 SH | Sept. 11, 2026 | Daily |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0.02% | 117,429 SH | Oct. 1, 2026 | Daily |
| VXF · VANGUARD INDEX FUNDS | 0.02% | 3,043,718 SH | Aug. 19, 2026 | Daily |
| VHT · VANGUARD WORLD FUND | 0.02% | 552,457 SH | Aug. 19, 2026 | Daily |
| TEXN · iShares Trust | 0.02% | 680 SH | Sept. 11, 2026 | Daily |
| FHLC · FIDELITY COVINGTON TRUST | 0.02% | 87,466 NS | July 31, 2026 | N-PORT |
| WSML · iShares Trust | 0.01% | 8,303 SH | Sept. 11, 2026 | Daily |
| DFAS · Dimensional ETF Trust | 0.00% | 78,390 NS | July 31, 2026 | N-PORT |
| TILT · FlexShares Trust | 0.00% | 9,954 NS | July 31, 2026 | N-PORT |
| ITOT · iShares Trust | 0.00% | 332,286 SH | Sept. 11, 2026 | Daily |
| IWV · iShares Trust | 0.00% | 70,755 SH | Sept. 11, 2026 | Daily |
| DCOR · Dimensional ETF Trust | 0.00% | 4,760 NS | July 31, 2026 | N-PORT |
| DFUS · Dimensional ETF Trust | 0.00% | 5,870 NS | July 31, 2026 | N-PORT |
| DFAU · Dimensional ETF Trust | 0.00% | 3,045 NS | July 31, 2026 | N-PORT |
| DFAC · Dimensional ETF Trust | 0.00% | 10,179 NS | July 31, 2026 | N-PORT |
| VTI · VANGUARD INDEX FUNDS | 0.00% | 9,141,487 SH | Aug. 19, 2026 | Daily |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0.00% | 20,636 SH | Aug. 19, 2026 | Daily |
| ISCB · iShares Trust | · | 9,303 SH | Sept. 11, 2026 | Daily |
TSHA Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside
rating · 18 analysts
BUY
Median target
$12.00
+159.2%
6 33.3%
Strong Buy
11 61.1%
Buy
1 5.6%
Hold
0 0.0%
Sell
0 0.0%
Strong Sell
12-Month Price Target
13 analysts · 2026-09-27Mean target $13.00 +180.8%
← Below all targets
Current price $4.63
Low$9.00
Mean$13.00
High$19.00
Peer comparison (GICS sub-industry) Key metrics vs sector peers
FY basis, prices as of each company's last fiscal year-end close.
| Ticker | Market Cap | P/E | Rev YoY | Net Margin | ROE | Gross Margin |
|---|---|---|---|---|---|---|
| TSHA | $1.57B | -16.2 | 17.3% | -1115.3% | -44.0% | · |
| STOK | $1.87B | -264.5 | 404.5% | -3.7% | -2.0% | · |
| ZYME | $1.97B | -24.4 | 38.9% | -76.6% | -26.9% | · |
| XNCR | $1.10B | -12.3 | 13.7% | -73.2% | -14.0% | · |
| SNDX | $1.84B | -6.4 | 627.8% | -165.6% | -257.1% | · |
| RARE | $2.22B | -3.9 | 20.2% | -85.4% | -1613.2% | · |
| COAG | · | · | · | · | · | · |
| ANAB | · | -105.4 | 157.0% | · | · | · |
| INBX | $1.15B | -8.7 | 550.0% | -10773.5% | -365.9% | · |
| TYRA | $1.41B | -13.1 | · | · | -42.7% | · |
Latest News Recent headlines mentioning this company
Taysha Gene Therapies (TSHA) Reports Financial Results for Q1 2026
Yahoo Finance · 4 months, 2 weeks ago
Canaccord Keeps Buy Rating on Taysha (TSHA) After Q1 Highlights
Yahoo Finance · 4 months, 2 weeks ago
Taysha Gene Therapies (TSHA) Stock Price Surges 343.45% From Year Ago Levels
Yahoo Finance · 5 months, 1 week ago
My Metrics Your personal watchlist — selected rows from Full Fundamentals
Pick the metrics that matter to you — click the + next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.
Source: SEC 10-Q filed Aug 11, 2026